Article

Bbarrons.com on 2021-01-08 15:20

A Case to Buy Regeneron Stock After Its Recent Tumble

In a note out Friday morning, Citi analyst Mohit Bansal says that weakness makes it a good time to buy.

Wall Street

Related news

Will Regeneron Stock Rebound After Its Recent 6% Fall?Forbes
Peers , Wall Street
BPayPal’s Recent Tumble Makes the Stock a Buy, Analyst Says barrons.com
Wall Street
BRegeneron Stock Jumps After Analyst Says Now Could Be a Good Time to Buy barrons.com
Coney Island
BRegeneron Stock Climbs as Earnings Come in Strong barrons.com
Wall Street , Como
BBuy Regeneron Stock, but Not Because of Its Covid-19 Antibody Cocktail, Analyst Says barrons.com
Stock Island
BA Promising Ebola Drug Isn’t Helping Regeneron Stock. Here’s Why.barrons.com
Washington , Wall Street , Democratic Republic of Congo
BRegeneron Stock Is Downgraded. Analyst Cites Tough Competition From a Novartis Drug.barrons.com
Wall Street , Stock Island
BWhat Sanofi Might Buy With Its Regeneron Windfall barrons.com
France , Windfall
BRegeneron Earnings Crushed Estimates barrons.com
Stock Island , Wall Street
MTechnical analysts see bargains after recent tumble in stock market marketwatch.com
United Kingdom , Wall Street , Everett
BRegeneron Stock Has Hit Its Peak, Says Citi barrons.com
MRegeneron to buy back $5 billion in stock as Sanofi sells part of its stake marketwatch.com
France
Stock indexes tumble while Treasury yields climb nwaonline.com
Washington , Wall Street
BRegeneron Stock Fell Despite Strong Earnings. This Is Why.2 min read barrons.com
Wall Street
BRegeneron Stock Rises as First-Quarter Earnings Top Forecasts1 min read barrons.com
Wall Street
BRegeneron Stock Sinks on Disappointing Sales of Eylea Vaccine1 min read barrons.com
Wall Street
BRegeneron Earnings Lift Stock. Here's Why.barrons.com
BWhat to Expect from Amgen and Regeneron Stock in 2020, According to an Analyst barrons.com
Americas , California , South San Francisco
MRegeneron stock up 2.2% after earnings beat marketwatch.com